<DOC>
	<DOCNO>NCT00405821</DOCNO>
	<brief_summary>This study determine whether acyclovir , medicine use treat herpes simplex virus 2 ( HSV-2 ) , slow progression ( worsen ) HIV disease people HIV HSV-2 infection . HSV-2 increase amount HIV virus blood infected people may make HIV progress faster . The study evaluate : `` Whether people take acyclovir avoid antiretroviral treatment later live `` Whether people take acyclovir get few genital ulcer `` How well people able take acyclovir side effect experience `` Differences amount HIV virus blood patient take acyclovir , HIV/AIDS different patient . People 18 year age old living Rakai district Uganda infect HIV ( early stage disease ) HSV-2 may eligible study . Participants randomly assign take study drug , acyclovir , placebo ( look-alike pill active ingredient ) daily 2 year . During time , visit clinic month routine physical examination . Patients develop genital ulcer complication HIV treat problem , patient whose HIV disease progress , require begin antiretroviral therapy , treat accordingly .</brief_summary>
	<brief_title>Acyclovir Treat Patients Co-infected With HIV Herpes Viruses Uganda</brief_title>
	<detailed_description>Interventions slow HIV-1 disease progression among person CD4+ count 250 cells/microliter could postpone need antiretroviral therapy ( ART ) prolong life-expectancy HIV-infected person . Herpes simplex virus type 2 ( HSV-2 ) show up-regulate HIV-1 replication cellular level . ( 1 ) This finding support clinical evidence individual HSV-2 seropositive time HIV-1 seroconversion high HIV viral load 5 15 month post-seroconversion . ( 2 ) Earlier study era zidovudine ( Retrovir ) monotherapy show survival advantage acyclovir ( ACV , Zovirax ) add treatment patient HIV . ( 3 ) Acyclovir prophylaxis show decrease herpes simplex virus infection varicella-zoster virus infection among HIV infect patient meta-analysis randomized trial North America Europe . This analysis also find reduce risk mortality among patient treat acyclovir . The potential acyclovir slow HIV-1 disease progression assess randomized trial Africa high rate HSV-2 infection observe among HIV-1 infected individual . This study propose assess benefit acyclovir prophylaxis among HIV-1 infected individual dually infect HSV-2 ART randomize double-blind placebo control trial .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Documentation HIV1 infection , either two positive ELISAs two discrepant ELISAs confirmatory positive Western Blot 2 . Documentation prior HSV2 infection Focus Kalon ELISA 3 . Absolute CD4+ Tcell count great equal 300 less equal 400 cells/microliter within 30 day prior randomization 4 . All participant must receive Cotrimoxazole prophylaxis part standard care unless contraindicate 5 . Age least 18 year 6 . Laboratory value ( within 30 day prior randomization ) 1 . Aspartate transaminase ( AST ) five time upper limit normal ( ULN ) 2 . Total bilirubin 2 time ULN 3 . Creatinine 2.0 mg/dL 4 . Platelet count least 50 000/microliter 5 . Hemoglobin least 8g/dL 7 . Written inform consent EXCLUSION CRITERIA : 1 . Concurrent malignancy disease state require cytotoxic chemotherapy 2 . Symptomatic significant HIVrelated illness ( WHO stage III IV ) , opportunistic infection malignancy mucocutaneous Kaposi 's sarcoma . A history AIDS defining opportunistic infection mucocutaneous Kaposi 's sarcoma candida treat tuberculosis 3 . Active HSV2 disease suggest painful genital ulcer disease time screen enrollment 4 . Current use antiretroviral medication Preventing MothertoChild Transmission ( PMTCT ) use antiretrovirals within previous 6 month 5 . Significant cardiac , pulmonary , kidney , rheumatologic , gastrointestinal , CNS disease detectable routine medical history , physical examination , screen laboratory study . 6 . Psychiatric illness , opinion PI , might interfere study compliance . 7 . Active substance abuse history prior substance abuse may interfere protocol compliance patient safety . 8 . CD4+ count less 300 400 cells/microliter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>AIDS</keyword>
	<keyword>HIV Disease Progression</keyword>
	<keyword>Quality Life</keyword>
	<keyword>HIV Viral Load</keyword>
	<keyword>Genital Ulcers</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>